用于哮喘的抗炎缓解疗法（AIR）
Anti-inflammatory reliever therapy (AIR) for asthma.
作者信息
Levy Mark L, Crooks Michael G
机构信息
Kenton Bridge Medical Centre, Harrow, UK.
Hull York Medical School, University of Hull, Hull, UK.
出版信息
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep.
Abstract
摘要
https://bit.ly/4aHOLn8. （此为网址，无法准确翻译为中文，保留原文即可）
相似文献
1
Anti-inflammatory reliever therapy (AIR) for asthma.
ERJ Open Res. 2024 Sep 30;10(5). doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep.
2
The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today.
J Allergy Clin Immunol Pract. 2024 Apr;12(4):870-879. doi: 10.1016/j.jaip.2024.01.011. Epub 2024 Jan 17.
3
Effective Asthma Management: Is It Time to Let the AIR out of SABA?
J Clin Med. 2020 Mar 27;9(4):921. doi: 10.3390/jcm9040921.
4
[Budesonide/formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma].
Med Klin (Munich). 2008 May 15;103(5):299-310. doi: 10.1007/s00063-008-1050-y.
5
It is time to change the way we manage mild asthma: an update in GINA 2019.
Respir Res. 2019 Aug 14;20(1):183. doi: 10.1186/s12931-019-1159-y.
6
Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma.
Curr Med Res Opin. 2007 Aug;23(8):1867-78. doi: 10.1185/030079907X210769.
7
The management of mild asthma.
Eur Respir J. 2021 Apr 8;57(4). doi: 10.1183/13993003.03051-2020. Print 2021 Apr.
8
What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?
Respirology. 2020 Aug;25(8):804-815. doi: 10.1111/resp.13804. Epub 2020 Mar 31.
9
The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription.
Adv Ther. 2023 Apr;40(4):1301-1316. doi: 10.1007/s12325-022-02410-z. Epub 2023 Jan 30.
10
SABAs as Reliever Medications in Asthma Management: Evidence-Based Science.
Adv Ther. 2023 Jul;40(7):2927-2943. doi: 10.1007/s12325-023-02543-9. Epub 2023 Jun 7.
本文引用的文献
1
Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials.
Eur Respir Rev. 2024 Apr 24;33(172). doi: 10.1183/16000617.0238-2023. Print 2024 Apr 30.
2
Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.
World Allergy Organ J. 2023 Oct 16;16(10):100823. doi: 10.1016/j.waojou.2023.100823. eCollection 2023 Oct.
3
Questions in Mild Asthma: An Official American Thoracic Society Research Statement.
Am J Respir Crit Care Med. 2023 Jun 1;207(11):e77-e96. doi: 10.1164/rccm.202304-0642ST.
4
Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.
ERJ Open Res. 2023 May 9;9(3). doi: 10.1183/23120541.00685-2022. eCollection 2023 May.
5
The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review.
J Allergy Clin Immunol Pract. 2023 Mar;11(3):762-772.e1. doi: 10.1016/j.jaip.2023.01.002. Epub 2023 Jan 10.
6
SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada).
ERJ Open Res. 2022 Sep 26;8(3). doi: 10.1183/23120541.00140-2022. eCollection 2022 Jul.
7
Over-prescription of short-acting β-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study.
J Asthma. 2023 Mar;60(3):574-587. doi: 10.1080/02770903.2022.2082305. Epub 2022 Jun 20.
8
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.
Thorax. 2022 Feb;77(2):199-202. doi: 10.1136/thoraxjnl-2021-217325. Epub 2021 Aug 6.
9
Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.
Cochrane Database Syst Rev. 2021 May 4;5(5):CD013518. doi: 10.1002/14651858.CD013518.pub2.
10
Identifying the drivers of patients' reliance on short-acting β2-agonists in asthma.
J Asthma. 2021 Aug;58(8):1094-1101. doi: 10.1080/02770903.2020.1761382. Epub 2020 May 29.
Zotero 插件